Publications by authors named "Seth Hopkins"

Claim this Profile
A
An open-label study on ulotaront's effects on insulin-glucose regulation in schizophrenia patients with metabolic syndrome and prediabetes: Part I.
Snezana Milanovic, Robert Lew, Kuangnan Xiong, Emily Casavant, Gerard Galluppi, Seth C Hopkins

Diabetes Obes Metab· January 2026

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A double-blind study on ulotaront's impact on weight-related parameters in schizophrenia patients with metabolic syndrome and prediabetes: Part II.
Snezana Milanovic, Robert Lew, Kuangnan Xiong, Emily Casavant, Gerard Galluppi, Seth C Hopkins

Diabetes Obes Metab· January 2026

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A brief visual evoked potential (VEP) modulation assessment of experience-dependent plasticity recorded via wireless dry-EEG headset in Phase 1 clinical units.
Esther C McWilliams, Snezana M Milanovic, Torbjørn Elvsåshagen, Robert Lew, Seth C Hopkins

Sci Rep· January 2026

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A Physiologically-Based Pharmacokinetic Model to Characterize Dasotraline Pharmacokinetics and CYP-mediated Drug-Drug Interactions.
Guangqing Xiao, Jing Lin, Yu-Luan Chen, Estela Skende, Seth C Hopkins

Drug Metab Bioanal Lett· January 2026

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Estimating heterogeneity of treatment effect in psychiatric clinical trials.
Joshua S Siegel, Jinglin Zhong, Sasagu Tomioka, Ajay Ogirala, Stephen V Faraone, Seth C Hopkins

J Psychiatr Res· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The trace amine-associated receptor 1 regulates presynaptic dopamine function: evidence from preclinical studies and a phase 1b trial in patients with schizophrenia.
Oliver D Howes, Luke J Vano, Alice E Petty, Grazia Rutigliano, Mattia Veronese, Seth C Hopkins

Biol Psychiatry· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Reduced Brain Iron and Striatal Hyperdopaminergia in Schizophrenia: A Quantitative Susceptibility Mapping MRI and PET Study.
Luke James Vano, Robert Ali McCutcheon, Jan Sedlacik, Stephen John Kaar, Grazia Rutigliano, Seth Cabot Hopkins

Am J Psychiatry· September 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Mesostriatal Dopaminergic Circuit Dysfunction in Schizophrenia: A Multimodal Neuromelanin-Sensitive Magnetic Resonance Imaging and [F]-DOPA Positron Emission Tomography Study.
Luke J Vano, Robert A McCutcheon, Grazia Rutigliano, Stephen J Kaar, Valeria Finelli, Seth C Hopkins

Biol Psychiatry· October 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A clinical trial inclusion criteria to enrich for patients presenting with canonical symptom structure in bipolar depression.
Seth C Hopkins, Sasagu Tomioka, Steven T Szabo, Kenneth S Koblan

Contemp Clin Trials· October 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Evaluating speech latencies during structured psychiatric interviews as an automated objective measure of psychomotor slowing.
Alex S Cohen, Zachary Rodriguez, Mark Opler, Brian Kirkpatrick, Snezana Milanovic, Seth Hopkins

Psychiatry Res· October 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Enrichment using speech latencies improves treatment effect size in a clinical trial of bipolar depression.
Joshua S Siegel, Alex S Cohen, Steven T Szabo, Sasagu Tomioka, Mark Opler, Seth Hopkins

Psychiatry Res· October 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Discovery and Model-Informed Drug Development of a Controlled-Release Formulation of Nonracemic Amisulpride that Reduces Plasma Exposure but Achieves Pharmacodynamic Bioequivalence in the Brain.
Seth C Hopkins, Siriporn Toongsuwan, Taryn J Corriveau, Takao Watanabe, Yuki Tsushima

Clin Pharmacol Ther· August 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
TAAR1 agonist ulotaront modulates striatal and hippocampal glutamate function in a state-dependent manner.
Sung M Yang, Ayan Ghoshal, Jeffrey M Hubbard, Florian Gackière, Romain Teyssié, Seth C Hopkins

Neuropsychopharmacology· June 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
TAAR1 agonist ulotaront delays gastric emptying of solids in patients with schizophrenia and concurrent metabolic syndrome with prediabetes.
Snežana Milanović, Nina Dedic, Robert Lew, Duane Burton, Kenneth S Koblan, Seth C Hopkins

Diabetes Obes Metab· June 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Evaluation of OCT2-mediated drug-drug interactions between ulotaront and metformin in subjects with schizophrenia.
Guangqing Xiao, Hironobu Tsukada, Yu-Luan Chen, Lei Shi, Seth C Hopkins

Pharmacol Res Perspect· April 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Estimating heterogeneity of treatment effect in psychiatric clinical trials.
Joshua S Siegel, Jinglin Zhong, Sasagu Tomioka, Ajay Ogirala, Stephen V Faraone, Seth C Hopkins

medRxiv· April 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
TAAR1 agonists improve glycemic control, reduce body weight and modulate neurocircuits governing energy balance and feeding.
Nina Dedic, Lien Wang, Eva Hajos-Korcsok, Jacob Hecksher-Sørensen, Urmas Roostalu, Seth C Hopkins

Mol Metab· February 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A Novel Method for Deriving Adverse Event Prevalence in Randomized Controlled Trials: Potential for Improved Understanding of Benefit-Risk Ratio and Application to Drug Labels.
Daria Piacentino, Ajay Ogirala, Robert Lew, Gregory Loftus, MaryAlice Worden, Seth C Hopkins

Adv Ther· January 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A Phase I, Open-Label, Fixed Sequence Study to Investigate the Effect of Cytochrome P450 2D6 Inhibition on the Pharmacokinetics of Ulotaront in Healthy Subjects.
Hironobu Tsukada, Yu-Luan Chen, Guangqing Xiao, Lisa Lennek, Snezana M Milanovic, Seth C Hopkins

Clin Pharmacokinet· December 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Interpreting clinical trial outcomes complicated by placebo response with an assessment of false-negative and true-negative clinical trials in depression using propensity-weighting.
Roberto Gomeni, Seth Hopkins, Françoise Bressolle-Gomeni, Maurizio Fava

Transl Psychiatry· December 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
U
Ulotaront: review of preliminary evidence for the efficacy and safety of a TAAR1 agonist in schizophrenia.
Eric D Achtyes, Seth C Hopkins, Nina Dedic, Heather Dworak, Courtney Zeni

Eur Arch Psychiatry Clin Neurosci· October 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effects of ulotaront on brain circuits of reward, working memory, and emotion processing in healthy volunteers with high or low schizotypy.
Francesca Perini, Jadwiga Maria Nazimek, Shane Mckie, Liliana P Capitão, Jessica Scaife, Seth C Hopkins

Schizophrenia (Heidelb)· August 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A multicenter, double-blind, placebo-controlled, randomized, Phase 1b crossover trial comparing two doses of ulotaront with placebo in the treatment of narcolepsy-cataplexy.
Steven T Szabo, Seth C Hopkins, Robert Lew, Antony Loebel, Thomas Roth

Sleep Med· July 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A randomized, single-dose, crossover study of the effects of ulotaront on electrocardiogram intervals in subjects with schizophrenia.
Hironobu Tsukada, Snezana M Milanovic, Borje Darpo, Hongqi Xue, Kuangnan Xiong, Seth C Hopkins

Clin Transl Sci· June 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Treatment with the novel TAAR1 agonist ulotaront is associated with reductions in quantitative polysomnographic REM sleep without atonia in healthy human subjects: Results of a post-hoc analysis.
John C Feemster, Sarah M Westerland, Thomas R Gossard, Tyler A Steele, Paul C Timm, Seth C Hopkins

Sleep Med· January 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis